DEERFIELD, Ill. — Walgreens Infusion Services on Monday announced that it has been selected as the preferred provider of home administration services for Makena (hydroxyprogesterone caproate injection), the only FDA-approved medication to help reduce the risk of preterm birth for clinically indicated patients. Makena is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
The new initiative, Makena @Home, creates access to weekly administration of the only FDA-approved medication for this indication in the home setting when covered by the patient’s insurance, providing an important option for patients and their healthcare providers. The program provides home administration of Makena by trained nurses, along with patient assessment and personalized care plan development, reimbursement/coverage coordination for home administration of therapy and scheduling and administrative support for patients.
“Makena is an important treatment for women at risk for recurrent preterm birth,” said Paul Mastrapa, president of Walgreens Infusion Services. “Makena @Home allows our expert multidisciplinary teams to care for patients in a comfortable and convenient location for them. We’re proud to add Makena @Home to the services we provide to patients in their homes and at alternate treatment sites nationwide each day.”
“Selecting Walgreens Infusion Services for Makena @Home gives us confidence that patients who need their weekly injections of FDA-approved Makena administered at home are receiving high-quality care,” said Greg Divis, CEO of K-V Pharmaceutical Company. “We’re excited to collaborate with a well-respected and widely recognized partner in Walgreens to provide this important option for the patients and providers we work with every day.”
Makena is administered by a healthcare provider as a single dose into the hip area (upper outer area of the buttocks) once a week, rotating sides each week. The goal of a healthy pregnancy is to deliver at term — at least 37 weeks of pregnancy. Makena is the only FDA-approved treatment that may help patients who have delivered preterm in the past stay pregnant longer.